TY - JOUR T1 - Evidence for absence of toxicity of T101 immunotoxin on human hematopoietic progenitor cells prior to bone marrow transplantation. A1 - Douay,L, AU - Gorin,N C, AU - Lopez,M, AU - Casellas,P, AU - Liance,M C, AU - Jansen,F K, AU - Voisin,G A, AU - Baillou,C, AU - Laporte,J P, AU - Najman,A, PY - 1985/1/1/pubmed PY - 1985/1/1/medline PY - 1985/1/1/entrez SP - 438 EP - 41 JF - Cancer research JO - Cancer Res VL - 45 IS - 1 N2 - T101-ricin A-chain immunotoxin is a hybrid molecule made up of the T101 monoclonal antibody bound to the A-chain of ricin. It specifically destroys cells expressing the cell surface T65 antigen. We have designed a preclinical study to evaluate its possible use for the in vitro treatment of T-cell hematological cancers prior to autologous bone marrow transplantation. The data presented here show that conditions previously defined to produce high tumor cell killing, i.e., a 20-hr incubation at 37 degrees in the presence of T101-ricin A-chain immunotoxin up to 10(-7) M in a 10 mM ammonium chloride solution, do not affect the in vitro proliferative capacity of human hematopoietic stem cells studied by means of semisolid medium cultures (granulocyte-macrophage progenitors, burst-forming units-erythrocyte) and continuous liquid cultures (pre-granulocyte-macrophage progenitors). Therefore, autologous bone marrow transplantation with T101-ricin A-chain immunotoxin-treated graft should be feasible. SN - 0008-5472 UR - https://www.unboundmedicine.com/medline/citation/3880666/Evidence_for_absence_of_toxicity_of_T101_immunotoxin_on_human_hematopoietic_progenitor_cells_prior_to_bone_marrow_transplantation_ L2 - http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=3880666 DB - PRIME DP - Unbound Medicine ER -